Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
delocamten
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Delocamten (MYK-224) is a next-generation, selective cardiac myosin inhibitor developed by Bristol Myers Squibb following its acquisition of MyoKardia. It is designed to address the underlying pathophysiology of heart failure with preserved ejection fraction (HFpEF) and hypertrophic cardiomyopathy (HCM) by reducing cardiac hypercontractility and improving diastolic function. Delocamten works by binding allosterically to cardiac myosin, shifting the myosin population toward a relaxed, "super-relaxed" (SRX) state. This mechanism decreases the number of active actin-myosin cross-bridges during systole, thereby reducing excessive contractility and facilitating better ventricular filling during diastole. It is currently being evaluated in Phase 2 clinical trials for HFpEF.
- Other names
- delocamten
02
Targets
MYH7 (Cardiac beta-myosin heavy chain)
Beyond the preview
Go deeper on delocamten.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on delocamten.